EUCTR2005-005039-86-IT进行中（未招募）不适用
A phase II study of Pegylated Liposomal Doxorubicin PLD as preoperative treatment for elderly patients with locally advanced primary breast cancer. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Women aged 66 years or older with histologically proven T2-4a-d, N0-3 any ER and PgR breast cancer. Patients not candidates to more intensive chemotherapy regimen according to clinician judgement .
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with other non-malignant uncontrolled systemic diseases that would preclude trial entry in the opinion of the investigator Specifically not eligible are patients with uncontrolled active infection, chronic infection such as active HBV or HCV. Patients with at least one of the so-called geriatric syndromes dementia, delirium, major depression. Patients with a history of any prior ipsilateral or contralateral invasive breast cancer. Prior neoadjuvant or adjuvant therapy for breast cancer.
研究者
相似试验
进行中（未招募）
不适用
PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER - PACLIDOX 07Operable breast cancer patients (T>2 cm, cT2-3, N0-N2, M0) or potentially operable, locally advanced breast cancer patients (T4, N0-2, M0) or inflammatory breast cancer patients (T4d, N0-2, M0), with or without HER2 overexpression or amplificationMedDRA version: 9.1Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantEUCTR2008-001369-27-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
进行中（未招募）
不适用
Phase II study of pegylated liposomal doxorubicin (Caelyxâ) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy - AROBASEBreast Cancer Patients with Brain MetastasesMedDRA version: 9.1Level: PTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-006790-81-FRAPREC50
Unknown
2 期
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast CancerMetastatic Breast CancerNCT01451580TTY Biopharm47
招募中
1 期
Phase I study of pegylated liposomal doxorubicin and cisplatin combination chemotherapy in patients with recurrent and refractory epithelial ovarian cancer.epithelial ovarian cancer, primary fallopian tube cancer, primary peritoneal cancerJPRN-UMIN000005798Cancer Institute Hospital18
已完成
3 期
Randomized Phase III Trail of Liposomal Doxorubicin(PLD)50mg/m2 versus Liposomal Doxorubicin(PLD)40mg/m2 in Patients with Platinum-Refractory and -Resistant Mullerian Carcinoma (Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma).Patients with platinum-refractory and -resistant Mullerian Carcinoma (epithelial ovarian, fallopian tube, primary peritoneal carcinoma)JPRN-UMIN000003130Japanese Gynecologic Oncology Group470